GlaxoSmithKline plc (GSK)
-NYSE | Prev Close: | 52.47 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 48.56 |
|---|
| Beta: | 0.47 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 41.68 - 54.00 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 2,896,590 |
|---|
| Market Cap: | 127.08B |
|---|
| P/E (ttm): | 19.18 |
|---|
| EPS (ttm): | 2.74 |
|---|
| Div & Yield: | 2.20 (4.20%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- The Top 3 Medical Uses of Botoxat Motley Fool(Tue, Jun 18)
- Sarepta And Eteplirsen: Will 12 Patients Be Enough For The FDA?at Seeking Alpha(Tue, Jun 18)
- 3 Views for Sarepta on Prosensa's IPOat Motley Fool(Tue, Jun 18)
- Apple’s iWatch Potential, GlaxoSmithKline Fields Drug Bid, and 3 More Hot Stocksat Wall St. Cheat Sheet(Tue, Jun 18)
- Teva to Acquire MicroDose TherapeutxZacks(Tue, Jun 18)
- Does Restless Legs Syndrome Really Shorten Life Span?at Motley Fool(Mon, Jun 17)
- Outside Review of Clinical Data Finds a Spinal Treatment’s Benefit Overstatedat New York Times(Mon, Jun 17)
- 5 Stocks Raising The Drugs Industry Higherat TheStreet(Mon, Jun 17)
- Is This Purchase a Game-Changer?at Motley Fool(Mon, Jun 17)
- Amicus Delays U.S. Approval Filing for Fabry Disease Drugat TheStreet(Mon, Jun 17)
- Genome Research Benefits Growing, Getting Cheaperat CNBC(Sun, Jun 16)
- A Big Pharma Company With a Juicy Dividend Yield and Low Valuationat Motley Fool(Sun, Jun 16)
- China Biotech In Review: Mindray Medical Buys U.S. Ultrasound Companyat Seeking Alpha(Sun, Jun 16)
- AstraZeneca's Buying Spree Bolsters Pipelineat Motley Fool(Sat, Jun 15)
- Uncle Sam Taps Big Pharma to Combat Antibiotic Resistanceat Motley Fool(Sat, Jun 15)
Key Statistics
| Forward P/E (1 yr): | 12.15 |
|---|
| P/S (ttm): | 3.01 |
|---|
| Ex-Dividend Date: | 08-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 4.01 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 2.9 |
|---|
| PEG Ratio (5 yr expected): | 4.12 |
|---|
Business Summary
GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide.
View More 
0.91%